Want to see STVN full AI Analyst Report?
STVN Stock Chart & Stats
$19.68
$0.21(1.07%)
At close: 4:00 PM EDT
$19.68
$0.21(1.07%)
Day’s Range― - ―
52-Week Range$12.89 - $28.00
Previous CloseN/A
Volume32.66K
Average Volume (3M)315.44K
Market Cap
$5.51B
Enterprise Value$4.14K
Total Cash (Recent Filing)$112.73M
Total Debt (Recent Filing)$448.52M
Price to Earnings (P/E)33.8
Beta0.84
Next Earnings
Aug 04, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)0.51
Shares Outstanding49,709,717
10 Day Avg. Volume256,276
30 Day Avg. Volume315,443
Financial Highlights & Ratios
PEG Ratio2.50
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.75Price Target Upside15.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.6
Revenue Forecast (FY)$1.28B
Bulls Say, Bears Say
Bulls Say
Biologics And GLP-1 Exposure Driving Durable Top-line GrowthStevanato’s outsized exposure to injectable biologics and GLP‑1 therapies reflects structural demand for advanced parenteral delivery. High growth in syringes and biologics signals lasting adoption of Stevanato’s formats and multi-year customer qualifications, supporting sustained revenue streams.
Rising Mix Of High-value Solutions Supports Margin DurabilityNearly half of revenue coming from high-value solutions increases pricing power and customer stickiness. These engineered, qualified products typically involve long qualification cycles and recurring volumes, which tend to stabilize margins and create multi-year revenue visibility versus commodity packaging.
Regulatory Approvals For Alina Pen Enable Product CommercializationEU marketing authorizations for the Alina pen convert prior development work into an addressable commercial product line. This is a structural revenue catalyst: it expands finished-device offerings, shortens customer go-to-market for combination products and supports long-term device and cartridge integration revenue.
Bears Say
Volatile And Modest Free Cash FlowPersistent free cash flow weakness, driven by heavy growth capex and multi‑year variability, undermines internal funding for expansion and dividends. Negative FCF relative to net income increases reliance on external funding and raises execution risk if capex ramps or working capital needs extend beyond forecasts.
Engineering Segment Revenue Collapse And Slow Order CyclesEngineering is project-driven with long sales cycles; a 31% drop signals weaker backlog and uncertain timing for recovery. This reduces business diversification and adds revenue volatility, making medium-term top-line improvement dependent on slow order conversion and sales/BD execution.
BDS Margin Compression From Depreciation, FX And TariffsMargin pressure in the core BDS segment from ramp-related depreciation, currency effects and tariffs erodes cash generation even as volumes grow. Sustained margin compression would reduce adjusted EBITDA conversion and constrain reinvestment unless offset by pricing, mix improvement or operational efficiencies.
Stevanato Group News
STVN FAQ
What was Stevanato Group Spa’s price range in the past 12 months?
Stevanato Group Spa lowest stock price was $12.89 and its highest was $28.00 in the past 12 months.
What is Stevanato Group Spa’s market cap?
Stevanato Group Spa’s market cap is $5.51B.
When is Stevanato Group Spa’s upcoming earnings report date?
Stevanato Group Spa’s upcoming earnings report date is Aug 04, 2026 which is in 2 days.
How were Stevanato Group Spa’s earnings last quarter?
Stevanato Group Spa released its earnings results on May 07, 2026. The company reported $0.127 earnings per share for the quarter, beating the consensus estimate of $0.119 by $0.008.
Is Stevanato Group Spa overvalued?
According to Wall Street analysts Stevanato Group Spa’s price is currently Undervalued.
Does Stevanato Group Spa pay dividends?
Stevanato Group Spa pays a Annually dividend of $0.062 which represents an annual dividend yield of 0.31%. See more information on Stevanato Group Spa dividends here
What is Stevanato Group Spa’s EPS estimate?
Stevanato Group Spa’s EPS estimate is 0.15.
How many shares outstanding does Stevanato Group Spa have?
Stevanato Group Spa has 49,709,717 shares outstanding.
What happened to Stevanato Group Spa’s price movement after its last earnings report?
Stevanato Group Spa reported an EPS of $0.127 in its last earnings report, beating expectations of $0.119. Following the earnings report the stock price went down -5.108%.
Which hedge fund is a major shareholder of Stevanato Group Spa?
Currently, no hedge funds are holding shares in STVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stevanato Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.75 (15.60% Upside)
$22.75 (15.60% Upside)
Blogger Sentiment
Bullish
STVN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 504.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
0.31%
Trailing 12-Months
Asset Growth
18.58%
Trailing 12-Months
Company Description
Stevanato Group Spa
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
STVN Company Deck
STVN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong top-line growth, robust Biopharmaceutical & Diagnostic Solutions momentum (notably syringes, biologics and GLP1 exposure), expanding high-value solution mix, margin expansion on an adjusted basis, and clear progress on strategic capacity investments. Offsetting these positives were a sharp revenue decline in the Engineering segment, segment-level gross margin compression for BDS driven by ramp-related depreciation, FX and tariff headwinds, a higher tax rate, modest free cash flow in the quarter due to heavy growth capex, and slower order conversion cycles in Engineering. Management reiterated full-year guidance and emphasized demand-driven capacity investment and operational optimization.View all STVN earnings summariesSTVN Stock 12 Month Forecast
Average Price Target
$22.75
▲(15.60% Upside)
Technical Analysis
Ownership Overview
2.77% Insiders
43.39% Mutual Funds
18.87% Other Institutional Investors
32.75% Public Companies and
Individual Investors